Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

- 27 April 2023 - 1 mins read

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Collette : trouver une communauté à travers la CBP

Diana : surmonter la spasticité avec sérénité

Diana: Taking spasticity in stride

See more stories

IPSEN – Buy-back programme – Art 5 of MAR –...

Ipsen delivered sales growth and margin expansion in 2020 –...

Ipsen delivers strong sales growth for the first nine months...

Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental...

Ipsen announces U.S. FDA submission acceptance of its supplemental New...

U.S. FDA approves Bylvay® for patients living with cholestatic pruritus...

IPSEN – Buy-back programme – Art 5 of MAR –...

Ipsen to present new data on clinical outcomes and patient...

Ipsen to present new data on clinical outcomes and patient...

Ipsen to present new data on clinical outcomes and patient...